Bladder cancer: new advances in management

Bladder cancer is the fifth most common cancer across Europe and in the UK, there are over 10,000 new cases each year.1 It is mostly diagnosed in patients over the age of 55 years with the average age at diagnosis currently 73 years.2 However, treatment options are limited, and survival rates are poor. The five-year survival rate for bladder cancers diagnosed in Europe is around 68% and over 65,000 patients died from it in 2018 alone.1,2 Urothelial carcinoma is the most common type of bladder cancer, accounting for 90% of all cases.3 Yet, between 15% and 18% of bladder cancer